8-K: Axsome Therapeutics Reports Strong Q3 2025 Growth

Axsome Therapeutics announced robust third-quarter 2025 financial results, driven by significant revenue growth across its marketed products and key advancements in its neuroscience pipeline.

Summary

• Total net product revenue for the third quarter of 2025 was $171.0 million, representing 63% year-over-year growth and 14% sequential growth.
• AUVELITY net product sales reached $136.1 million in Q3 2025, an increase of 69% year-over-year and 14% sequentially.
• SUNOSI net product revenue was $32.8 million for Q3 2025, growing 35% year-over-year and 9% sequentially.
• SYMBRAVO generated $2.1 million in net product sales during its first full quarter of commercialization in Q3 2025.
• Net loss for Q3 2025 improved to $47.2 million, or $(0.94) per share, compared to a net loss of $64.6 million, or $(1.34) per share, in Q3 2024.
• Cash and cash equivalents totaled $325.3 million at September 30, 2025, up from $315.4 million at December 31, 2024.
• A supplemental New Drug Application (sNDA) for AXS-05 in Alzheimer's disease agitation was submitted to the FDA.
• The FOCUS Phase 3 trial evaluating solriamfetol in adults with ADHD was completed, meeting primary and key secondary endpoints with rapid, substantial, and statistically significant reductions in ADHD symptoms.
• The company anticipates several clinical trial initiations and an NDA submission in Q4 2025, with topline results for other programs expected in 2026.

Sentiment

Score: 8

Explanation: The company demonstrated exceptional financial performance with significant year-over-year revenue growth across all marketed products, coupled with a substantial reduction in net loss. The robust pipeline execution, including a key sNDA submission for a Breakthrough Therapy designated candidate and positive Phase 3 results, de-risks future growth. The stated cash runway into cash flow positivity further strengthens the financial position. These factors collectively indicate strong operational momentum and significant future value creation potential.

Positives

• Total net product revenue increased 63% year-over-year to $171.0 million in Q3 2025.
• AUVELITY net product sales grew 69% year-over-year to $136.1 million, with approximately 209,000 prescriptions written in Q3 2025 (+46% YoY).
• SUNOSI net product revenue increased 35% year-over-year to $32.8 million, with approximately 53,000 prescriptions written in Q3 2025 (+12% YoY).
• SYMBRAVO generated $2.1 million in net product sales in its first full quarter of commercialization, with approximately 5,000 prescriptions reported.
• Net loss improved to $47.2 million in Q3 2025 from $64.6 million in Q3 2024.
• Cash and cash equivalents increased to $325.3 million at September 30, 2025, from $315.4 million at December 31, 2024.
• Current cash is believed to be sufficient to fund anticipated operations into cash flow positivity.
• Submitted a supplemental NDA for AXS-05 in Alzheimer's disease agitation, which has FDA Breakthrough Therapy designation.
• Completed the FOCUS Phase 3 trial for solriamfetol in adults with ADHD, demonstrating rapid, substantial, and statistically significant reductions in ADHD symptoms.
• AUVELITY payer coverage is approximately 85% of all lives covered, including 75% commercial and 100% government.
• Contracted with a third large group purchasing organization (GPO) for potential formulary coverage of AUVELITY.
• SUNOSI payer coverage remains at approximately 83% of all lives covered, with 95% commercial and 60% government.
• Contracted with a second large GPO for SYMBRAVO.
• NDA submission for AXS-12 for cataplexy in narcolepsy is anticipated in Q4 2025.
• Initiation of a Phase 3 trial for AXS-14 in fibromyalgia is anticipated in Q4 2025, building on rapid and robust efficacy demonstrated in previous Phase 2 and Phase 3 trials.
• Maintains a robust intellectual property portfolio with patent protection extending into the 2040s for key products.

Negatives

• The company continues to operate at a net loss of $47.2 million for the quarter.
• Selling, general, and administrative (SG&A) expenses significantly increased to $150.2 million in Q3 2025 from $95.6 million in Q3 2024, primarily due to commercialization activities and sales force expansion.
• Total cost of revenue increased to $11.9 million in Q3 2025 from $8.4 million in Q3 2024.
• A non-cash charge for contingent consideration of $13.2 million was recorded in Q3 2025.

Risks

• The commercial success of SUNOSI, AUVELITY, and SYMBRAVO products and the ability to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05.
• The ability to maintain and expand payer coverage for products.
• The success, timing, and cost of ongoing and anticipated clinical trials, including the timing of initiation, pace of enrollment, completion, futility analyses, receipt of interim results, and data readouts.
• The ability to fully fund disclosed clinical trials, assuming no material changes to currently projected revenues or expenses.
• The timing of and ability to obtain and maintain U.S. Food and Drug Administration (FDA) or other regulatory authority approval of, or other action with respect to, product candidates.
• The ability to successfully defend intellectual property or obtain necessary licenses at an acceptable cost, if at all.
• The ability to successfully resolve any intellectual property litigation, and whether applicable federal agencies will approve of such settlements.
• The successful implementation of research and development programs and collaborations.
• The success of license agreements.
• The acceptance by the market of products and product candidates, if approved.
• Anticipated capital requirements, including the amount of capital required for commercialization and launch of other product candidates, if approved, and the potential impact on the anticipated cash runway.
• The ability to convert sales to recognized revenue and maintain a favorable gross to net sales.
• Unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts, or a global pandemic and other factors, including general economic conditions and regulatory developments, not within control.

Future Outlook

Axsome Therapeutics anticipates continued substantial and sustained growth, driven by robust commercial performance and pipeline execution. The company expects to initiate pivotal Phase 2/3 trials for AXS-05 in smoking cessation, Phase 3 trials for solriamfetol in pediatric ADHD and MDD with EDS, and a Phase 3 trial for AXS-14 in fibromyalgia in Q4 2025. An NDA submission for AXS-12 for narcolepsy is also expected in Q4 2025. Topline results for solriamfetol in binge eating disorder (ENGAGE trial) and shift work disorder (SUSTAIN trial) are anticipated in 2026. The company believes its current cash is sufficient to fund anticipated operations into cash flow positivity, based on its current operating plan.

Management Comments

• "Axsome posted strong revenue growth in the third quarter driven by contributions from all three of our marketed products."
• "Our broad development pipeline continues to advance, and we recently submitted our supplemental NDA for AXS-05 for the treatment of Alzheimer's disease agitation, a serious condition affecting millions of patients in the U.S., and a critical unmet medical need."
• "With robust commercial performance and pipeline execution, Axsome is well positioned to continue delivering substantial and sustained growth and transformative new medicines for patients living with serious CNS disorders."

Industry Context

Axsome Therapeutics operates in the central nervous system (CNS) disorders market, a high-impact area with significant unmet medical needs. The company's focus on novel mechanisms of action and differentiated products aligns with industry trends seeking more effective and targeted treatments for conditions like major depressive disorder, Alzheimer's agitation, narcolepsy, and migraine. The strong growth of AUVELITY and SUNOSI suggests successful market penetration in competitive therapeutic areas, while the advancing pipeline for conditions like ADHD, binge eating disorder, and fibromyalgia positions Axsome to address broader CNS challenges. The company's strategy of expanding payer coverage and GPO contracts reflects a common industry approach to enhance market access and drive product adoption.

Comparison to Industry Standards

• AUVELITY is highlighted as the first and only rapid-acting oral NMDA receptor antagonist and sigma-1 receptor agonist approved for MDD, positioning it uniquely against other antidepressants.
• AUVELITY demonstrated rapid remission as early as week 2 and sustained improvement through week 6, along with symptom improvement starting at week 1, which are strong efficacy markers in the MDD treatment landscape.
• SUNOSI is presented as the first and only dopamine and norepinephrine reuptake inhibitor for excessive daytime sleepiness in narcolepsy or OSA, with proven wakefulness improvement through 9 hours and 90% patient satisfaction at 150 mg, indicating strong performance in its class.
• SYMBRAVO's novel, oral, rapidly-absorbed, multi-mechanistic approach for acute migraine treatment, achieving pain freedom and return to normal functioning within 2 hours, positions it competitively among acute migraine therapies.
• AXS-05's FDA Breakthrough Therapy designation for Alzheimer's disease agitation underscores its potential to address a critical unmet medical need, aligning with the industry's pursuit of innovative solutions for neurodegenerative disorders.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, improved net loss, positive cash runway outlook, and significant pipeline advancements, indicating potential for future value creation.
• Patients: Potential for new and improved treatment options for serious CNS disorders, including Alzheimer's disease agitation, ADHD, MDD with EDS, binge eating disorder, shift work disorder, narcolepsy, and fibromyalgia.
• Employees: Continued company growth and pipeline expansion may lead to job stability and potential for further career opportunities.
• Customers (Healthcare Providers): Expanded product portfolio and improved payer coverage for existing products offer more diverse and accessible treatment choices for patients.
• Suppliers/Partners: Sustained commercial success and active R&D activities may strengthen existing relationships and create new business opportunities.

Next Steps

• FDA decision on acceptance of the sNDA for AXS-05 in Alzheimer's disease agitation.
• Initiate pivotal Phase 2/3 trial of AXS-05 in smoking cessation in Q4 2025.
• Initiate Phase 3 trial of solriamfetol in children and adolescents with ADHD in Q4 2025.
• Initiate Phase 3 trial of solriamfetol in MDD patients with EDS in Q4 2025.
• Submit NDA to the FDA for AXS-12 for the treatment of cataplexy in narcolepsy in Q4 2025.
• Initiate Phase 3 trial of AXS-14 in fibromyalgia in Q4 2025.
• Anticipate topline results from the ENGAGE Phase 3 trial of solriamfetol in binge eating disorder in 2026.
• Anticipate topline results from the SUSTAIN Phase 3 trial of solriamfetol in shift work disorder in 2026.
• Host a conference call and webcast on November 3, 2025, at 8:00 a.m. Eastern Time to discuss results.

Key Dates

Recommendation

The company demonstrated exceptional financial performance with significant year-over-year revenue growth across all marketed products, coupled with a substantial reduction in net loss. The robust pipeline execution, including a key sNDA submission for a Breakthrough Therapy designated candidate and positive Phase 3 results, de-risks future growth. The stated cash runway into cash flow positivity further strengthens the financial position. These factors collectively indicate strong operational momentum and significant future value creation potential, making it a compelling investment opportunity.

Keywords

Axsome Therapeutics, AXSM, biopharmaceutical, CNS disorders, major depressive disorder, MDD, Alzheimer's disease agitation, narcolepsy, obstructive sleep apnea, OSA, migraine, ADHD, binge eating disorder, BED, shift work disorder, SWD, fibromyalgia, AUVELITY, SUNOSI, SYMBRAVO, AXS-05, solriamfetol, AXS-12, AXS-14, Q3 2025 results, financial results, pipeline, sNDA, NDA, clinical trials, revenue growth, neuroscience